logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11690819 B1

PDFFull Text
Date of Patent:
Jul. 04, 2023

Filed:

Feb. 28, 2022

Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease

Applicant:

Impel Pharmaceuticals Inc., Seattle, WA (US);

Inventors:

John D. Hoekman, Seattle, WA (US);

Kelsey H. Satterly, Seattle, WA (US);

Inna Dashevsky, Seattle, WA (US);

Aditya R. Das, Foster City, CA (US);

Stephen B. Shrewsbury, Fallbrook, CA (US);

Gregory J. Davies, Issaquah, WA (US);

Bhavin Y. Gajera, Bellevue, WA (US);

Assignee:

Impel Pharmaceuticals Inc., Seattle, WA (US);

Attorney:

Fenwick & West LLP

Primary Examiner:

Sin J Lee

Int. Cl.
CPC ...
A61K 31/198 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 31/165 (2006.01); A61M 11/02 (2006.01); A61M 15/00 (2006.01); A61M 15/08 (2006.01); A61P 25/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/198 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 9/0075 (2013.01); A61K 9/14 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 9/48 (2013.01); A61K 31/165 (2013.01); A61M 11/02 (2013.01); A61M 15/003 (2014.02); A61M 15/0035 (2014.02); A61M 15/0036 (2014.02); A61M 15/08 (2013.01); A61P 25/16 (2018.01); A61M 15/009 (2013.01); A61M 2202/04 (2013.01); A61M 2202/064 (2013.01); A61M 2205/8225 (2013.01); A61M 2206/20 (2013.01);
Abstract

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Find Patent Forward Citations

Loading…